Lonza Group AG (LZAGF)
Data as of September 4, 2026 · Medical - Diagnostics & Research
Stockbruh grade: Mixed 2/5 metrics rated Sunny
What does Lonza Group AG do?
Lonza Group AG supplies various products and services for pharmaceutical, biotech, and nutrition markets. They develop and manufacture biopharmaceuticals, small molecule drugs, and cell and gene therapies. Based in Basel, Switzerland, they offer specialty raw materials and technology solutions. 🧪🧬💊.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ⛈️ Weak | 5-year price performance |
| Profitability | ☀️ Strong | Net margin & return on equity |
| Growth | ⛈️ Weak | Revenue & earnings trend |
| Earnings | ⛅ Moderate | EPS vs analyst expectations |
| Cash & Debt | ☀️ Strong | Balance sheet strength |
| Price | $736.20 | Market Cap | — |
| Exchange | Other OTC | | |
Plain-English Analysis
What's it worth?
Returns have been below average recently — worth reviewing valuation carefully before investing. Sign up free to see the full Stockbruh valuation breakdown.
How the business works
Lonza Group AG supplies various products and services for pharmaceutical, biotech, and nutrition markets. They develop and manufacture biopharmaceuticals, small molecule drugs, and cell and gene therapies. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Growth has been challenging recently. Revenue or earnings are showing weak trends. Sign up free to see the full picture including forward projections.
What's ahead?
Earnings are mixed. Sign up free for the full earnings picture including EPS history and analyst forecasts.